Remiges led the Series A round of finance for Phost'In Therapeutics in France

Phost’in Therapeutics (Montpellier, France), a biopharmaceutical company focused on the discovery and development of N-glycosylation inhibitors, today announced that it has successfully secured a €10.3 million Series A round, from an international syndicate of Life Science and Innovation Investors led by Remiges Ventures and completed by ANRI and Irdi Soridec Gestion. The Series A funding will be used to advance the clinical development of Phost’in’s main program, PhOx430, and to enhance capacity of its discovery platform.